SONUS Pharmaceuticals, Inc. (Bothel...

SONUS Pharmaceuticals, Inc. (Bothell, WA) reported initial efficacy consequence s for Tocosol paclitaxel from the dose escalation stage of four Phase 2 clinical trials in non-small small room lung cancer, bladder cancer, ovarian cancer, and colorectal cancer. The accrues to date demonstrate objective antitumor answers in all four cancers and a disease direction rate ranging from 37% to 89% To date, 73 bring under rules from the dose escalation stage of the Phase 2 studies are evaluable for efficacy, including 18 in each of the non-small small room lung, bladder, and colorectal studies, and 19 bring under rules in ...